The rapid progress in genomics and proteomics technologies creates a unique opportunity for understanding the mechanisms of action and the toxicities of compounds. The application of gene-expression and protein-expression profiling promises to improve the predictive power of safety assessment, resulting in the development of drug candidates with a higher efficacy and a lower toxicity. Additionally, in the later phases of drug development, surrogate markers of treatment efficacy and toxicity can be applied to optimise the monitoring of pre-clinical and clinical studies.
CelisJ.E., KruhøfferM., GromovaI., FrederiksenC., ØstergaardM., ThykjaerT., GromovP., YuJ., PálsdóttirH., MagnussonN., & ØrntoftT. F. (2000). Gene expression in profiling: monitoring transcription and translation products using DNA microarrays and proteomics. FEBS Letters480, 2–16.
3.
AndersonN.G., & AndersonN.L. (1996). Twenty years of two-dimensional electrophoresis: past, present and future. Electrophoresis17, 443–453.
4.
AicherL., WahD., ArceA., GrenetO., & SteinerS. (1998). New insights into cyclosporine A nephrotoxicity by proteome analysis. Electrophoresis19, 1998–2003.
5.
SeiberH., BallsM., FentemJ.H., BianchiV., ClothierR.H., DierickxP.J., EkwallB., GarleM.J., Gómez-LechónM.J., GribaldoL., GüldenM., LiebschM., RasmussenE., RougetR., ShrivastavaR., & WalumE. (1996). Acute toxicity testing in vitro and the classification and labelling of chemicals. The report and recommendations of ECVAM workshop 16. ATLA24, 499–510.
6.
EkwallB. (1992). Validation of in vitro cytotoxicity tests. In In Vitro Alternatives to Animal Pharmaco-Toxicology (ed. CastellJ.V., & Gómez-LechónM.J.), pp. 361–390. Madrid, Spain: Farmaindustria.
7.
NicholsonJ.K., LindonJ.C., & HolmesE. (1999). Metabonomics: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica29, 1181–1189.
